Physician profile
Marcos E Cota
NPI 1073287298
$2,026.07
in general payments reported to CMS, 2019-2025
15 companies · $720 in 2025
The $720 reported for 2025 was more than what 78% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $113 · 2023: $400 · 2024: $793 · 2025: $720.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,913.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,912.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $414.21 | 2024-2025 | |
| Glaxosmithkline, LLC. | $300.46 | 2023-2025 | Arexvy, Shingrix, Bexsero |
| Viiv Healthcare Company | $209.59 | 2022-2025 | Apretude |
| Astrazeneca Pharmaceuticals LP | $202.80 | 2024-2025 | Farxiga |
| Amgen INC. | $189.16 | 2024 | Krystexxa |
| Pfizer INC. | $122.08 | 2024 | |
| Novo Nordisk INC | $116.78 | 2025 | Wegovy |
| Teva Pharmaceuticals USA, INC. | $113.55 | 2025 | Austedo Xr |
| Gilead Sciences, INC. | $106.52 | 2023 | Epclusa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.93 | 2023 | Jardiance |
| Merck Sharp & Dohme LLC | $73.78 | 2023-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Alkermes, INC. | $23.88 | 2025 | Vivitrol |
| Horizon Therapeutics Plc | $22.75 | 2023 | Krystexxa |
| Sanofi Pasteur INC. | $20.52 | 2025 | |
| Lilly USA, LLC | $19.06 | 2025 | Mounjaro, Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcos Cota listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.